Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does NATALIZUMAB Cause Infection susceptibility increased? 39 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 39 reports of Infection susceptibility increased have been filed in association with NATALIZUMAB (TYRUKO). This represents 0.1% of all adverse event reports for NATALIZUMAB.

39
Reports of Infection susceptibility increased with NATALIZUMAB
0.1%
of all NATALIZUMAB reports
1
Deaths
11
Hospitalizations

How Dangerous Is Infection susceptibility increased From NATALIZUMAB?

Of the 39 reports, 1 (2.6%) resulted in death, 11 (28.2%) required hospitalization, and 1 (2.6%) were considered life-threatening.

Is Infection susceptibility increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for NATALIZUMAB. However, 39 reports have been filed with the FAERS database.

What Other Side Effects Does NATALIZUMAB Cause?

Multiple sclerosis relapse (6,478) Fatigue (4,456) Multiple sclerosis (4,078) Memory impairment (3,024) Malaise (2,523) Fall (2,481) Headache (2,476) Gait disturbance (2,427) Prescribed underdose (2,162) Maternal exposure during pregnancy (1,948)

What Other Drugs Cause Infection susceptibility increased?

ADALIMUMAB (179) ETANERCEPT (160) OCRELIZUMAB (118) METHOTREXATE (95) PREDNISONE (67) DIMETHYL (64) MYCOPHENOLATE MOFETIL (64) PREDNISOLONE (62) SECUKINUMAB (59) TOFACITINIB (57)

Which NATALIZUMAB Alternatives Have Lower Infection susceptibility increased Risk?

NATALIZUMAB vs NATALIZUMAB-SZTN NATALIZUMAB vs NATAMYCIN NATALIZUMAB vs NATEGLINIDE NATALIZUMAB vs NAVITOCLAX NATALIZUMAB vs NAXITAMAB-GQGK

Related Pages

NATALIZUMAB Full Profile All Infection susceptibility increased Reports All Drugs Causing Infection susceptibility increased NATALIZUMAB Demographics